About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
F
Is HSCT Necessary to Consolidate Hematological Remission After CAR-T in ALL?
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Francesco Saglio
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Francesco Saglio
0 views
February 16, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
22:37
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
Feat.
T. Badar
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
Feat.
C. Lai
23:15
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
Feat.
M. Levis
09:42
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…
Feat.
M. Al Malki
16:28
Fred Hutchinson Cancer Center
Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …
Feat.
R. Cassaday
04:08
GRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
13:26
Steven Pavletic
Chronic GvHD: Main Complications After ASCT
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
The Improbable History of CAR T-Cells
Feat.
C. June
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
The Truth About Current Consensus Statements on Hematopoietic Cell T…
Feat.
R. Gale
20:18
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…
Feat.
M. Hamilton
31:41
MyCancerHaven
Treating Adults With Newly Diagnosed ALL
Feat.
R. Vij,
A. Patel
28:10
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell To…
Feat.
D. Reeves
04:02
Michael Burke
Updated Results from the BLAST and TOWER Studies: Safety and Efficac…
28:07
Indy Hematology Review
Controversies and Recommendations for the Treatment of ALL and Lymph…
Feat.
W. Stock
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course
Overview of Hematopoietic Cell Transplantation
Feat.
R. Salit
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
07:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…
Feat.
L. Shune
